Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06016127
NCT06016127CompletedNot Applicable

A Single-center, Randomized, Pilot Study to Assess Iovera° Lumbar Medial Branch Cryoneurolysis vs Lumbar Radiofrequency Ablation for Facet Mediated Chronic Low Back Pain

Medical Pain Management Services, PLLC2 sites in 1 country30 target enrollmentStarted: June 18, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
30
Locations
2
Primary Endpoint
Safety of Cryoneurolysis as Compared to Radiofrequency Ablation (RFA)
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a single-center, randomized, pilot study in adult subjects with facet mediated CLBP. Thirty (30) subjects are planned for initial enrollment and will be randomized 1:1 to receive ioveraº medial branch cryoneurolysis or radiofrequency ablation.

Detailed Description

This is a single-center, randomized, pilot study in adult subjects with facet mediated CLBP. Thirty (30) subjects are planned for initial enrollment and will be randomized 1:1 to receive ioveraº medial branch cryoneurolysis or radiofrequency ablation.

This study is designed to determine if a full efficacy RCT can be successfully conducted using the procedures and protocols described in the current pilot study protocol, or if protocol modifications are necessary before moving forward with a full efficacy RCT. Furthermore, the study will assess the feasibility of the outcome measurements employed, construct a foundation for sample size calculation, and the acceptability/practicality of conducting the full efficacy RCT.

Randomization to treatment groups according to the randomization assignment will be performed on the day of treatment. The treatment groups are:

  • Group 1: subjects will receive iovera° cryoneurolysis to the medial branch nerves of the lumbar spine
  • Group 2: subjects will receive RFA to the medial branch nerves of the lumbar spine

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Masking Description

Open label

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Male or female volunteers, at least 18 years of age at screening
  • •Primary complaint of axial low-back pain suggestive of unilateral or bilateral facet joint involvement (i.e., facet mediated CLBP)
  • •Low back pain is chronic (i.e., > 3 months' duration)
  • •Low back pain score of ≥ 4 (i.e., moderate pain) on the 0 to 10 NRS or functional impairment at screening
  • •Successful trial of two diagnostic medial branch blocks consisting of two positive blocks with local anesthetic only (i.e., no steroids) that results in at least 50% relief of primary (index) pain for the duration of the local anesthetic used or history of a positive response to prior radiofrequency treatment (i.e., ≥ 6 months prior to enrollment)
  • •Failure of at least three months of conservative non-operative therapy (e.g., physical therapy, chiropractic care, spinal injections, NSAIDs or other appropriate analgesics),
  • •Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments

Exclusion Criteria

  • •Active workers' compensation, personal injury, Social Security disability insurance (SSDI), or other litigation/compensation related to the spine
  • •Serious spinal disorders (verified on magnetic resonance imaging (MRI)) that may impact outcomes, including any of the following:
  • •Suspected cauda equina syndrome (e.g., bowel/bladder dysfunction)
  • •Traumatic fracture
  • •Systemic inflammatory spondyloarthropathy
  • •Lumbar radiculopathy/radiculitis (i.e., root irritation and deficit)
  • •Neurogenic claudication
  • •Prior lumbar spinal fusion surgery
  • •Comorbidity that, in the judgment of the Investigator, may affect the subject's ability to participate in the study including lumbar radiculopathy and neuropathic pain disorder
  • •Currently pregnant, nursing, or planning to become pregnant during the study
  • •Known contraindication to study devices, including any of the following:
  • •Cryoglobulinemia
  • •Paroxysmal cold hemoglobinuria
  • •Cold urticaria
  • •Raynaud's disease
  • •Open and/or infected wounds at or near the treatment site
  • •Coagulopathy
  • •3.5-inch needle cannot be used in the low back region because of habitus
  • •Severe chronic pain disorder that in the opinion of the investigator may impact postsurgical outcomes
  • •Presence of any of the following:
  • •Spinal neurostimulator
  • •Intrathecal analgesic drug pump
  • •Current manifestation of poorly controlled mental illness that in the opinion of the investigator may meaningfully impact treatment outcomes, including any of the following:
  • •Mood disorder (e.g., major depression, bipolar)
  • •Psychotic disorder (e.g., schizophrenia)
  • •Subject received other spine intervention/therapies in the 30 days prior to block administration (e.g., spinal injections, minimally invasive therapies, surgical therapies)
  • •Subject received radiofrequency ablation in the low back region ≤ 6 months before study enrollment
  • •History, suspicion, or clinical manifestation of:
  • •Alcohol abuse or dependence
  • •Illicit drug use
  • •Opioid abuse or dependence (≥40 mg MED PO/day in past 30 days) Given the COVID-19 pandemic, the subject must be medically fit/cleared for treatment by the investigator. If there is a concern about a subject's recent or potential exposure to COVID-19, or if the subject is not medically fit/cleared for treatment due to suspected COVID-19 illness/symptoms (or other serious illness), the subject must be excluded per Exclusion criterion #4.

Outcomes

Primary Outcomes

Safety of Cryoneurolysis as Compared to Radiofrequency Ablation (RFA)

Time Frame: 0-12 months

Safety will be assessed as the number of subjects with reported treatment-related adverse related to cryoneurolysis or RFA.

Secondary Outcomes

  • Pain Intensity as Measured by 11-point Numeric Rating Scale (NRS) at 12 Month Follow up(12 months)

Investigators

Sponsor
Medical Pain Management Services, PLLC
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Active, not recruiting
Not Applicable
Study for Evaluating the Efficacy of Ciprofol in Patients Under Narcotic Sleep With Chronic InsomniaChronic Insomnia
NCT04958382Sichuan Provincial People's Hospital30
Completed
Not Applicable
Pilot Study of the Ablative Fractional CO2 Laser in Hypertrophic Scars in Adult Burn PatientsBurns
NCT03240718Centre hospitalier de l'Université de Montréal (CHUM)12
Recruiting
Not Applicable
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R MutationNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
NCT06102928Kunming Medical University30
Completed
Phase 2
A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)Hepatitis D, Chronic
NCT02731131Hoffmann-La Roche12
Completed
Not Applicable
Study to Evaluate the Effectiveness of High Dose Statin Loading in Acute Heart Failure PatientsAcute Heart Failure
NCT01127945Yonsei University50